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CORRESPONDENCE
A case with a cytogenetically cryptic variant of the
inv(16)(p13q22)/t(16;16)(p13;q22)
Acute myeloid leukemia (AML) with the inv(16)(p13q22) or
t(16;16)(p13;q22) is a specific clinico-biological entity with
predominant abnormal monocytic and eosinophil differen-
tiation; however, occasional cases have been described
without the characteristic bone marrow eosinophilia (1).
The inv(16)/t(16;16) is found in 4% of cytogenetically
abnormal AML and is associated with a better prognosis
(2,3). The inv(16)(p13q22)/t(16;16)(p13;q22) leads to a
fusion between the core binding factor B gene (CBFB) on
16q22 and the smooth muscle myosin heavy chain gene
(MYH11) on 16p13. The inv(16)/t(16;16) can be routinely
detected by cytogenetic examination, fluorescence in situ
hybridization (FISH), or reverse transcriptase PCR. Here, we
describe a case with a cytogenetically cryptic variant of the
inv(16), due to an insertion of 16p13 into 16q22.
A 57-year-old female patient was admitted with chest
pain, mild fever, and a leg wound that was not responding
to antibiotics. Lab examination revealed anemia (hemoglobin
7.2 g/dL), an elevated leukocyte count (34.5  109/L, with 0.6
 109/L neutrophils), and thrombocytopenia (43  106/L).
Coagulation results were normal.
A peripheral blood smear showed an excess of myeloblasts.
Bone marrow examination revealed the presence of a popu-
lation of blast cells (37%), an increased percentage of (pro)
monocytes, and suppression of erythroid and megakaryocytic
proliferation. A diagnosis of AML-M4 was confirmed according
to the French-American-British (FAB) classification.
Cytogenetic analysis showed a normal karyotype (46,XX
[20/20]); however, unexpectedly, PCR was positive for a type
A CBFB/MYH11 fusion transcript.
The patient was treated according to the “Hovon 102”
AML protocol, consisting of remission induction with idar-
ubicin and cytarabine, followed by two consolidation courses:
daunorubicin and cytarabine, and etoposide and mitoxan-
trone. After the first cycle, a complete morphological remis-
sion was obtained, persisting for 6 and 9 months after
diagnosis. A 13 log reduction of the CBFB/MYH11 tran-
script occurred 6 months after diagnosis. At 8 months, the
fusion transcript remained stable. The patient relapsed 10
months after diagnosis at morphological (60% blasts in bone
marrow) and molecular levels.
Cytogenetic analyses at diagnosis showed R-banded
metaphases that were of good quality without evidence of an
inv(16) (Figure S1).
The LSI CBFB/16q22 Break Apart Rearrangement Probe
(Abbott Molecular, Des Plaines, IL) showed a normal hy-
bridization pattern in 10 of 10 metaphases and in 198 of
200 interphase nuclei; however, an XL CBFB/MYH11
translocation-dual fusion probe (Metasystems) revealed an
abnormal hybridization pattern in 70 of 100 interphase cells
and in 8 of 10 metaphase cells. In metaphases, a pattern
was observed, in which part of the MYH11 probe was
inserted into 16q22, without reciprocal translocation of
CBFB to 16p, whereas the expected pattern in an inv(16) is
one fusion signal on 16p13 and one fusion signal on 16q22
(Figures S2 and S3). FISH analysis with the dual color/dual
fusion probe revealed an insertion of 16p13 into 16q22, as
a cytogenetically cryptic variant of the inv(16)(p13q22)/
t(16;16)(p13;q22). An experiment with three probes (XL
CBFB/MYH11 translocation-dual fusion probe, and in-house
designed subtelomere probes (16p and 16q)) confirmed that
the subtelomere of 16q was on the same arm as 16q22,
proving the insertion of 16p13 into 16q22 and ruling out a
variant. This resolves the discrepancy between the normal
cytogenetic result and the positive CBFB-MYH11 fusion
transcript.
To our knowledge, this is only the second reported case of
AML with a CBFB/MYH11 transcript resulting from a cyto-
genetically cryptic insertion of 16p13 into 16q22 (3). One
other case of AML with a CBFB fusion transcript, a normal
karyotype, and a normal FISH result with break-apart CBFB
probes was also described (4).
According to present European Leukemia Net (ELN)
recommendation, the molecular detection of an inv(16) is
optional in AML with a normal karyotype, and is mandatory
only in the case of mitotic failure, poor banding, or cyto-
logical features suggestive of AML with inv(16). This
observation illustrates that, in rare cases, this may lead to a
failure to correctly diagnose AML with inv(16): indeed,
there was no cytological indication of AML with inv(16),
despite metaphases of good quality. In addition, the widely
used LSI CBFB break-apart rearrangement probe also
yielded a normal result because no separation of the
centromeric and telomeric CBFB (16q22) flanking regions
occurred in this case. This case suggests that it might be
prudent to always perform cytogenetic analysis in combi-
nation with molecular detection of the CBFB-MYH11 tran-
script. If, alternatively, molecular detection of the fusion is
done by FISH, dual color/dual fusion probe sets are rec-
ommended, because the cryptic insertion will escape
detection by the widely used LSI CBFB/16q22 Break Apart
Rearrangement Probe.
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